Skip to content

Dietary Intervention of Stress-Induced Neurovegetative Disorders With a Specific Amino Acid Composition (asn01)

Dietary Intervention of Stress-Induced Neurovegetative Disorders in Men and Women With a Specific Amino Acid Composition With Micronutrients

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01425983
Acronym
asn01
Enrollment
80
Registered
2011-08-30
Start date
2011-03-31
Completion date
2012-06-30
Last updated
2015-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Imbalance of Constituents of Food Intake, Nervous System Disorder

Keywords

stress, lability and irritative disturbances, dietary supplement, amino acid composition, psychological neurological questionnaire (PNF)

Brief summary

Psychosocial stress leads to altered neuroendocrine functions, such as serotonergic dysfunction, as well as alterations of the autonomic nervous system and the hypothalamic-pituitary-adrenal (HPA) axis activity resulting in an imbalance between inhibitory and excitatory neurotransmitters. Clinical consequences include, inter alia, neurovegetative disorders, higher resting heart rate, hypertension, depressive symptoms, sleep disturbances, irregular body-weight changes, and insulin resistance. Poor dietary intake of the essential amino acid L-tryptophane as a precursor to 5-hydroxytryptamine (HT, serotonin) increases sensitivity to stress. It is therefore the investigators hypothesis that daily oral administration of an amino acid mixture (dosage 3.8 g/day) with micronutrients specifically designed to decrease neurovegetative disorders will target these neuroendocrine and metabolic alterations in adults with psychosocial stress. The principal endpoints will be a decrease in points in the psychological-neurological questionnaire (PNF).

Interventions

DIETARY_SUPPLEMENTamino acid composition (asn01)

Amino acid composition with micronutrients, once a day (in the evening, 2 hours after dinner) content of a sachet mixed with 200 ml water. Duration: 12 weeks

OTHERPlacebo

Placebo; once a day (in the evening, 2 hours after dinner) content of a sachet mixed with 200 ml water. Placebo contains no amino acids and micronutrients and is identical in appearance and solution properties. Duration: 12 weeks

Sponsors

Kyberg Vital GmbH
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Age: 18-65 Years * Psychological-Neurological Questionnaire (PNF): 30 - 50 Points

Exclusion criteria

* Age: \< 18 and \> 65 Years * Psychological neurological questionnaire (PNF): \< 30 and \> 50 Points * Resting heart rate: \< 70/min * Supplementation with dietary supplements or drugs which contains amino acids, vitamins and other micronutrients * Therapy with antipsychotic drugs such as tranquilizer, antidepressants * acute and chronic diarrhea * Psychological-neurological or psychiatric therapy

Design outcomes

Primary

MeasureTime frameDescription
Psychological neurological questionnaire (PNF)12-week dietary interventionPre-post intervention changes in total number of points PNF

Secondary

MeasureTime frameDescription
Psychological neurological questionnaire (PNF)12-week dietary interventionPre-post improvement in total number of points from the psychological-neurological questionnaire (PNF) about 10 Points or more
Salivary cortisol concentration (30 minutes after waking in the morning)12-week dietary interventionAbsolute difference between cortisol concentration at baseline and 12 weeks
Salivary cortisol concentration (in the evening between 8 and 10 pm, 2 hours after dinner)12-week dietary interventionAbsolute difference between cortisol concentration at baseline and 12 weeks
Serotonin concentration in blood12-week dietary interventionAbsolute difference between serotonin concentration at baseline and 12 weeks

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 17, 2026